KRAS and colorectal carcinoma: Presence of KRAS mutations in primary CRC portends a poor response to monotherapy and combination therapy using anti-EGFR mAB cetuximab or panitumumab (Amado et al, 2008; Karapetis et al, 2008; Lievre et al, 2008).